The impact of pharmacokinetic gene profiles across human cancers

Michael T. Zimmermann, Terry M Therneau, Jean-Pierre Kocher

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The right drug to the right patient at the right time is one of the ideals of Individualized Medicine (IM) and remains one of the most compelling promises of the post-genomic age. The addition of genomic information is expected to increase the precision of an individual patient's treatment, resulting in improved outcomes. While pilot studies have been encouraging, key aspects of interpreting tumor genomics information, such as somatic activation of drug transport or metabolism, have not been systematically evaluated. Methods: In this work, we developed a simple rule-based approach to classify the therapies administered to each patient from The Cancer Genome Atlas PanCancer dataset (n=2858) as effective or ineffective. Our Therapy Efficacy model used each patient's drug target and pharmacokinetic (PK) gene expression profile, the specific genes considered for each patient depended on the therapies they received. Patients who received predictably ineffective therapies were considered at high-risk of cancer-related mortality and those who did not receive ineffective therapies were considered at low-risk. The utility of our Therapy Efficacy model was assessed using per-cancer and pan-cancer differential survival. Results: Our simple rule-based Therapy Efficacy model classified 143 (5%) patients as high-risk. High-risk patients had age ranges comparable to low-risk patients of the same cancer type and tended to be later stage and higher grade (odds ratios of 1.6 and 1.4, respectively). A significant pan-cancer association was identified between predictions of our Therapy Efficacy model and poorer overall survival (hazard ratio, HR=1.47, p=6.3×10-3). Individually, drug export (HR=1.49, p=4.70×10-3) and drug metabolism (HR=1.73, p=9.30×10-5) genes demonstrated significant survival associations. Survival associations for target gene expression are mechanism-dependent. Similar results were observed for event-free survival. Conclusions: While the resolution of clinical information within the dataset is not ideal, and modeling the relative contribution of each gene to the activity of each therapy remains a challenge, our approach demonstrates that somatic PK alterations should be integrated into the interpretation of somatic transcriptomic profiles as they likely have a significant impact on the survival of specific patients. We believe that this approach will aid the prospective design of personalized therapeutic strategies.

Original languageEnglish (US)
Article number577
JournalBMC Cancer
Volume18
Issue number1
DOIs
StatePublished - May 21 2018

Fingerprint

Pharmacokinetics
Genes
Neoplasms
Survival
Therapeutics
Pharmaceutical Preparations
Precision Medicine
Atlases
Patient Rights
Genomics
Transcriptome
Disease-Free Survival
Odds Ratio
Genome
Gene Expression
Mortality

Keywords

  • Cancer treatment protocols
  • Genomic interpretation
  • Individualized medicine
  • Pharmacokinetics
  • Transcriptome profiling

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

The impact of pharmacokinetic gene profiles across human cancers. / Zimmermann, Michael T.; Therneau, Terry M; Kocher, Jean-Pierre.

In: BMC Cancer, Vol. 18, No. 1, 577, 21.05.2018.

Research output: Contribution to journalArticle

@article{a22d90d13375458e8cb488c3bf1424bf,
title = "The impact of pharmacokinetic gene profiles across human cancers",
abstract = "Background: The right drug to the right patient at the right time is one of the ideals of Individualized Medicine (IM) and remains one of the most compelling promises of the post-genomic age. The addition of genomic information is expected to increase the precision of an individual patient's treatment, resulting in improved outcomes. While pilot studies have been encouraging, key aspects of interpreting tumor genomics information, such as somatic activation of drug transport or metabolism, have not been systematically evaluated. Methods: In this work, we developed a simple rule-based approach to classify the therapies administered to each patient from The Cancer Genome Atlas PanCancer dataset (n=2858) as effective or ineffective. Our Therapy Efficacy model used each patient's drug target and pharmacokinetic (PK) gene expression profile, the specific genes considered for each patient depended on the therapies they received. Patients who received predictably ineffective therapies were considered at high-risk of cancer-related mortality and those who did not receive ineffective therapies were considered at low-risk. The utility of our Therapy Efficacy model was assessed using per-cancer and pan-cancer differential survival. Results: Our simple rule-based Therapy Efficacy model classified 143 (5{\%}) patients as high-risk. High-risk patients had age ranges comparable to low-risk patients of the same cancer type and tended to be later stage and higher grade (odds ratios of 1.6 and 1.4, respectively). A significant pan-cancer association was identified between predictions of our Therapy Efficacy model and poorer overall survival (hazard ratio, HR=1.47, p=6.3×10-3). Individually, drug export (HR=1.49, p=4.70×10-3) and drug metabolism (HR=1.73, p=9.30×10-5) genes demonstrated significant survival associations. Survival associations for target gene expression are mechanism-dependent. Similar results were observed for event-free survival. Conclusions: While the resolution of clinical information within the dataset is not ideal, and modeling the relative contribution of each gene to the activity of each therapy remains a challenge, our approach demonstrates that somatic PK alterations should be integrated into the interpretation of somatic transcriptomic profiles as they likely have a significant impact on the survival of specific patients. We believe that this approach will aid the prospective design of personalized therapeutic strategies.",
keywords = "Cancer treatment protocols, Genomic interpretation, Individualized medicine, Pharmacokinetics, Transcriptome profiling",
author = "Zimmermann, {Michael T.} and Therneau, {Terry M} and Jean-Pierre Kocher",
year = "2018",
month = "5",
day = "21",
doi = "10.1186/s12885-018-4345-2",
language = "English (US)",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The impact of pharmacokinetic gene profiles across human cancers

AU - Zimmermann, Michael T.

AU - Therneau, Terry M

AU - Kocher, Jean-Pierre

PY - 2018/5/21

Y1 - 2018/5/21

N2 - Background: The right drug to the right patient at the right time is one of the ideals of Individualized Medicine (IM) and remains one of the most compelling promises of the post-genomic age. The addition of genomic information is expected to increase the precision of an individual patient's treatment, resulting in improved outcomes. While pilot studies have been encouraging, key aspects of interpreting tumor genomics information, such as somatic activation of drug transport or metabolism, have not been systematically evaluated. Methods: In this work, we developed a simple rule-based approach to classify the therapies administered to each patient from The Cancer Genome Atlas PanCancer dataset (n=2858) as effective or ineffective. Our Therapy Efficacy model used each patient's drug target and pharmacokinetic (PK) gene expression profile, the specific genes considered for each patient depended on the therapies they received. Patients who received predictably ineffective therapies were considered at high-risk of cancer-related mortality and those who did not receive ineffective therapies were considered at low-risk. The utility of our Therapy Efficacy model was assessed using per-cancer and pan-cancer differential survival. Results: Our simple rule-based Therapy Efficacy model classified 143 (5%) patients as high-risk. High-risk patients had age ranges comparable to low-risk patients of the same cancer type and tended to be later stage and higher grade (odds ratios of 1.6 and 1.4, respectively). A significant pan-cancer association was identified between predictions of our Therapy Efficacy model and poorer overall survival (hazard ratio, HR=1.47, p=6.3×10-3). Individually, drug export (HR=1.49, p=4.70×10-3) and drug metabolism (HR=1.73, p=9.30×10-5) genes demonstrated significant survival associations. Survival associations for target gene expression are mechanism-dependent. Similar results were observed for event-free survival. Conclusions: While the resolution of clinical information within the dataset is not ideal, and modeling the relative contribution of each gene to the activity of each therapy remains a challenge, our approach demonstrates that somatic PK alterations should be integrated into the interpretation of somatic transcriptomic profiles as they likely have a significant impact on the survival of specific patients. We believe that this approach will aid the prospective design of personalized therapeutic strategies.

AB - Background: The right drug to the right patient at the right time is one of the ideals of Individualized Medicine (IM) and remains one of the most compelling promises of the post-genomic age. The addition of genomic information is expected to increase the precision of an individual patient's treatment, resulting in improved outcomes. While pilot studies have been encouraging, key aspects of interpreting tumor genomics information, such as somatic activation of drug transport or metabolism, have not been systematically evaluated. Methods: In this work, we developed a simple rule-based approach to classify the therapies administered to each patient from The Cancer Genome Atlas PanCancer dataset (n=2858) as effective or ineffective. Our Therapy Efficacy model used each patient's drug target and pharmacokinetic (PK) gene expression profile, the specific genes considered for each patient depended on the therapies they received. Patients who received predictably ineffective therapies were considered at high-risk of cancer-related mortality and those who did not receive ineffective therapies were considered at low-risk. The utility of our Therapy Efficacy model was assessed using per-cancer and pan-cancer differential survival. Results: Our simple rule-based Therapy Efficacy model classified 143 (5%) patients as high-risk. High-risk patients had age ranges comparable to low-risk patients of the same cancer type and tended to be later stage and higher grade (odds ratios of 1.6 and 1.4, respectively). A significant pan-cancer association was identified between predictions of our Therapy Efficacy model and poorer overall survival (hazard ratio, HR=1.47, p=6.3×10-3). Individually, drug export (HR=1.49, p=4.70×10-3) and drug metabolism (HR=1.73, p=9.30×10-5) genes demonstrated significant survival associations. Survival associations for target gene expression are mechanism-dependent. Similar results were observed for event-free survival. Conclusions: While the resolution of clinical information within the dataset is not ideal, and modeling the relative contribution of each gene to the activity of each therapy remains a challenge, our approach demonstrates that somatic PK alterations should be integrated into the interpretation of somatic transcriptomic profiles as they likely have a significant impact on the survival of specific patients. We believe that this approach will aid the prospective design of personalized therapeutic strategies.

KW - Cancer treatment protocols

KW - Genomic interpretation

KW - Individualized medicine

KW - Pharmacokinetics

KW - Transcriptome profiling

UR - http://www.scopus.com/inward/record.url?scp=85047362003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047362003&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4345-2

DO - 10.1186/s12885-018-4345-2

M3 - Article

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 577

ER -